Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $73.69 million versus the consensus estimate of $77.33 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.